XOMA Reports Third Quarter 2008 Financial Results MarketWatch - Nov 10, 2008 The $0.2 increase resulted primarily from higher sales of LUCENTIS(r) inside and outside the US and RAPTIVA(r) outside the US XOMA's research and ...XOMA
Source: Google News
Recent News and Articles on the Keywords: prevent blindness + lucentis + blindness Related to the article below (Last Update: 8/5/2008)
? Macular Degeneration Clinical Trial WHOI, IL - Aug 4, 2008 According to the organization, Prevent Blindness America?, about 1.65 million Americans have AMD. The most important risk factor is age. ...
Costly drug poses dilemma Calgary Herald, Canada - Jul 28, 2008 The CNIB calls the therapy a "breakthrough" drug for its success in treating age-related wet macular degeneration, the leading cause of blindness in Canada. ...
SEC Form 8-K Current Report.pdf Sydney Morning Herald, Australia - Jul 8, 2008 The disease has been estimated to affect 175000 people in the United States and to have resulted blindness in approximately 30000 people in the US Retisert, ...
Source: Google News
Intravitreal Avastin: The Low Cost Alternative to Lucentis? - PJ Rosenfeld - American Journal of Ophthalmology, 2006 - Elsevier ... for the closely related drug known as Lucentis (ranibizumab, Genentech, Inc), 3
and 4 the presence of an enormous unmet need to preventblindness from VEGF ...
Short-term intraocular pressure trends following BJ Ophthalmol - British Medical Journal, 2008 - bjo.bmj.com ... age-related macular intravitreal injections of ranibizumab (Lucentis) Short-term ...
sharmasr@ ohsu.edu Acknowledgements: Research to PreventBlindness, New York ...
Seeing the Light: AMD Therapies Starting to Emerge from the Pipeline A Options, TOC Latest - Pharmaceutical & Diagnostic Innovation, 2004 - ingentaconnect.com ... injection is an advantage over potential competitors like Lucentis and Macugen ... is
a poten- tial candidate for gene therapy to preventblindness in individuals ...
Drug delivery strategies to treat age-related macular degeneration - O Olejnik, P Hughes - Advanced Drug Delivery Reviews, 2005 - Elsevier ... cause of irreversible blindness in patients ... Genaera Corporation), Ranibizumab (Lucentis),
Retaane (Alcon ... The blood?retinal barriers prevent most systemically ...
Pharmacokinetics of Intravitreal Ranibizumab (Lucentis) - SJ Bakri, MR Snyder, JM Reid, JS Pulido, MK Ezzat, … - Ophthalmology, 2007 - Elsevier ... Ranibizumab (Lucentis, Genentech Inc., San Francisco, CA) is a recombinant humanized ...
by an unrestricted grant from Research to PreventBlindness, New York, New ...
Looking beyond Lucentis on the management of macular degeneration - EC Fletcher, NV Chong - Eye, 2008 - nature.com ... Many treatments for angiogenesis help to prevent the formation ... study in those who
can be benefited from Lucentis. ... the current leading cause of blindness in the ...
Persisent ocular hypertension following intravitreal ranibizumab SJ Bakri, CA McCannel, AO Edwards, DM Moshfeghi - Graefe's Archive for Clinical and Experimental Ophthalmology, 2008 - Springer ... Intravitreal ranibizumab (Lucentis, Genentech, San Francisco, CA, USA) is an anti ...
an unrestricted departmental grant from Research to PreventBlindness, New York ... -
Specific interventions help, but don't explain variations in heart attack survival, researchers say
WEDNESDAY, July 5 (HealthDay News) -- Standard hospital quality assessments don't always reflect the outcomes of patients treated at particular centers, according to a U.S. study that looked at death rates for heart attack patients.
Researchers at Yale University School of Medicine analyzed 2002-2003 data from 962 hospitals on heart attack patients who were age 66 or older. They also looked at publicly reported hospital performance data from the Centers for Medicare & Medicaid Services.
There was significant correlation between some hospital measures and risk-standardized, 30-day death rates, the researchers found. However, these measures accounted for only 6 percent of hospital-level variation in 30-day death rates for heart attack patients.
The study identified moderately strong correlations between use of heart drugs such as beta-blockers at both hospital admission and discharge, aspirin use at admission and discharge, and angiotensin-converting enzyme (ACE) inhibitor use.
It also found weaker, but statistically significant, correlations between these medication measures and smoking cessation counseling and time to reperfusion therapy measures.
"This finding suggests that a hospital's short-term mortality rates after [heart attack] cannot be reliably inferred from performance on the publicly reported process measures," the Yale team concluded in a prepared statement.
Their report was published in the July 5 issue of the Journal of the American Medical Association.
A new drug that's been shown to prevent a major form of blindness among the elderly has been approved by the U.S. Food and Drug Administration.
Genentech's Lucentis (ranibizumab), dosed monthly, was approved to treat wet age-related macular degeneration. Wet AMD, a retinal disease that causes irreversible vision loss, affects about 155,000 Americans annually, the FDA said in a statement.
The disease is caused when abnormal blood cells in the retina leak, eventually damaging the portion of the eye responsible for central vision. In clinical testing of Lucentis, nearly 95 percent of users maintained vision after 12 months, compared with 60 percent of participants who did not take Lucentis.
Another Genentech medication, the cancer drug Avastin, is increasingly prescribed "off-label" to treat AMD, the Associated Press reported. While both inhibit the protein that's believed responsible for the disease, Avastin costs about $17 a dose, while Lucentis is likely to cost upwards of $2,000 a dose, the wire service said.
At least 10,000 people with macular degeneration have been legally prescribed Avastin off-label, meaning that the FDA hasn't sanctioned the drug for that purpose, the AP reported. Genentech has said it has no plans to test Avastin's safety and effectiveness for AMD, the wire service said.
More information
To learn more about age-related macular degeneration, visit amd.org.
